Le Lézard
Classified in: Health
Subjects: CHI, WOM, BLK

Prolacta Bioscience® Applauds the National Black Nurses Association Safe Human Donor Milk Resolution Calling for Higher Donor Milk Safety and Screening Standards


DUARTE, Calif., Aug. 17, 2017 /PRNewswire/ -- Prolacta Bioscience, the pioneer in human milk-based neonatal nutritional products for premature infants, applauds the National Black Nurses Association (NBNA) for its effort to improve the safety and quality of the nation's human donor milk supply. The NBNA recently approved a new resolution requesting the U.S. Food and Drug Administration (FDA) implement regulations to provide babies who receive donor milk with the same protections as people receiving blood donations and transfusions, and calls for all premature infants to receive an exclusive human milk diet (EHMD)[1].

Prolacta Bioscience Logo (PRNewsfoto/Prolacta Bioscience)

The preterm birth rate among non-Hispanic black women is 48 percent higher than the rate among all other women, according to a March of Dimes report cited in the NBNA resolution. The NBNA drafted the resolution to raise awareness of the potential risks in the donor milk supply, and to emphasize the need for better protections for African American babies who receive donor milk.

"The NBNA supports the need for regulations and laws that increase the safety of the U.S. human donor milk supply," said Dr. Eric J. Williams, NBNA President. "Human milk is the best source of nutrition for babies, especially those born prematurely, and we are passionate about advocating for improved quality and access to human milk for all premature infants and their families."

Three states ? California, Maryland and New York ? regulate human milk as a tissue and require licensing of donor milk banks, according to the NBNA resolution. Although the FDA views human milk as a food, and has done preliminary exploration of current safety practices and standards, there are no FDA regulations in the human donor milk industry.

"We applaud the NBNA for advocating for higher quality and safety standards to improve the human donor milk supply," said Scott Elster, CEO of Prolacta. "By extending the same safety and screening standards that are in place for donor blood and donor plasma to donor milk, we can ensure the fragile population of premature infants has access to a safe human donor milk supply."

The NBNA resolution, "Creating a Culture of Safety with Human Donor Milk," notes that, "With the growth of internet commerce, anyone can go to Craigslist.com, Facebook.com, or even athletes' supplement websites to buy human milk that is completely untested and unprocessed; it is time for the federal government to recognize that human milk carries the same risks as other biologics such as blood and plasma."

The NBNA suggests the following procedures to regulate human donor milk:

The NBNA is the nation's largest professional organization for African American nurses and represents more than 150,000 African American nurses with 94 chapters in 35 states.

About Prolacta Bioscience
Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based neonatal nutritional products to meet the needs of critically ill, premature infants in the neonatal intensive care unit (NICU). Prolacta leads the industry in the quality and safety of nutritional products made from donor breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk.

www.prolacta.com

[1] An EHMD is when 100% of the protein, fat and carbohydrates in an infant's intake are derived solely from human milk.

 

SOURCE Prolacta Bioscience


These press releases may also interest you

at 16:45
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered...

at 16:30
Today, the Biden-Harris Administration released a final rule under Section 1557, the core nondiscrimination provision of the Affordable Care Act. This groundbreaking rule marks a critical step in protecting access to health care and coverage for...

at 16:14
eNeura, a pioneering leader in therapeutic solutions, proudly announces a monumental milestone in its journey towards revolutionizing migraine treatment. With unwavering commitment to innovation and patient well-being, eNeura has already reached...

at 16:10
bluebird bio, Inc. today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December...

at 16:10
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual...

at 16:00
This program will support individuals in Putnam County with Opioid Use Disorder and co-occurring substance use and mental health conditions through peer support and harm reduction for the broader Putnam County community. A...



News published on and distributed by: